Tuesday, February 24, 2015

Flexus Biosciences Acquired For $1.25 Billion

San Carlos-based Flexus Biosciences, which is developing cancer therapeutics, has been acquired by Bristol-Myers Squibb. The deal is worth $1.25 billion, split between $800M upfront and earnout worth up to $450M. Flexus Biosciences was venture backed by Kleiner Perkins Caufield and Byers, The Column Group, Celgene, and Amgen.